Larvol Cliniclarvol.hashnode.devยทAug 8, 2024Phase I Study of ARX788 in HER2-Positive Metastatic Breast Cancer: Safety and EfficacyPurpose: ARX788 is a novel antibody-drug conjugate (ADC) comprised of an anti-HER2 mAb and a potent tubulin inhibitor payload AS269 that is site-specifically conjugated to the antibody via a nonnatural amino acid incorporated into the antibody. Herei...CancerAdd a thoughtful commentNo comments yetBe the first to start the conversation.
